化学镀法制备32P放射性支架预防血管成形术后再狭窄的实验研究

目的：评价^32P放射性支架对兔髂动脉狭窄的预防作用。方法：以化学镀法制备^32P放射支架，与普通支架配对后，随机植入兔双侧髂动脉，于术前、术后即刻及术后30d血管造影观察动脉狭窄程度，病理组织学观察内膜面积及管腔内径的变化。结果：术后30d，两种支架植入后的动脉最小腔径（MLD）均较术后即刻显著减小，放射性支架组的MLD显著大于对照组（P＜0．01），而其后期丢失、丢失指数、狭窄程度3项指标则显著小于对照组（P＜0．01）。两种支架植入均使血管内膜增生；放射性支架侧血管管腔面积显著大于对照侧（P＜0．05），而其新生内膜面积显著小于对照侧（P＜0．01）。两种支架植入后对支架边缘部位均无影响。结论：化学镀法制备的新型32P放射性支架安全有效，较低的放射活度即可有效防止支架内狭窄；短球囊扩张支架可能会避免边缘部位狭窄的发生。     

全反式维甲酸对防治经皮冠脉介入治疗后再狭窄的临床疗效观察

目的观察不同剂量全反式维甲酸（ATRA）对防治经皮冠脉介入治疗（PCI）后再狭窄（Rs）的疗效。方法2004年7月至2005年9月连续入院行PCI的冠心病300例。随机分为全反式维甲酸正常剂量组（10mgt．i．d p．o，甲组）、强化剂量组（20mgt．i．d p．o，乙组）、对照组（丙组）。6个月后分别比较甲乙丙三组的再狭窄率、心脏事件发生率和心功能。结果300例患者中男性228例、女性72例。住院期间甲乙丙三组比较：心绞痛9％VS8％VS9％；再次急性心肌梗死（AMI）O％VS2％VS1％；再次缺血性血运重建（TVR）3％VS2％VS3％；心源性死亡4％VS6％VS4％，P〉0．05，无显著统计学差异。随访期间三组比较：心绞痛12％VS9％VS20％；再次AMII％VSO％VS1％；心源性死亡2％VS4％VS4％，P〉0．05，无显著统计学差异；再狭窄率3／33（9．1％）VS2／30（6．7％）VS12／32（37．5％）；TVR3％VS2％VS11％，P〈0．05，有显著统计学差异。结论常规剂量ATRA防治再狭窄安全有效。     

Prevention of Restenosis after Coronary Angioplasty with Low-Density Lipoprotein Apheresis

Abstract: A prospective study was performed to determine whether low-density lipoprotein (LDL) apheresis, when performed only immediately before and after percutaneous transluminal coronary angioplasty (PTCA), is effective in preventing restenosis of coronary artery lesions following PTCA. Thirty-six patients with coronary heart disease (CHD) and hypercholesterolemia were divided into 2 groups. The 9 patients in the LDL group underwent LDL-apheresis 1 day before and 5 days after PTCA while the 27 patients of the control group underwent PTCA but did not undergo LDL-apheresis. Follow-up coronary angiography (CAG) was performed 4 months after PTCA. The rate of restenosis of coronary artery lesions was significantly lower in the LDL group (0%) than in the control group (30%). These findings suggest that LDL-apheresis, when performed before and after PTCA, is effective in preventing restenosis of coronary artery lesions in patients with CHD and hypercholesterolemia.     

覆膜支架在外周血管病变中的应用

覆膜支架在外周血管病变中主要用于各种原因引起的动脉瘤、假性动脉瘤和其他动静脉畸形,最近有人将其应用于创伤性病变和PTA、TIPS等介入操作之中,效果显著,但是术后内皮化进程较长以及较高的再狭窄率仍是困扰覆膜支架临床应用进一步发展的主要原因。     

Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor

Thirty percent of patients undergoing percutaneous transluminal coronary angioplasty develop recurrent disease within a year. This is usually due to the rapid accumulation of intimal smooth muscle cells and extracellular matrix, which causes luminal narrowing, and is probably orchestrated by several mitogenic and chemotactic factors, of which platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) appear to be particularly important. We have investigated the effects of administering a combination of neutralizing antibodies directed against PDGF-BB and bFGF on neo-intima development following balloon catheter injury in the rat carotid artery. Purified sheep anti-PDGF-BB and anti-bFGF immunoglobulins (IgGs) were administered singly and in combination prior to mechanical injury and daily until sacrifice, 8 days later. Plasma titres of exogenous anti-PDGF-BB and anti-bFGF were maintained at levels 10–20-fold higher than those required to neutralise the mitogenic and chemotactic effects of 20 ng/ml of PDGF-BB, or 10 ng/ml bFGF in vitro. Used singly, anti-PDGF IgG treatment was associated with a 47% reduction in intimal thickness and a 59% reduction in intimal:medial area ratio; anti-bFGF IgG administration caused a 53% reduction in intimal thickness, and a 50% reduction in intimal:medial area ratio. Treatment with a combination of these antibodies resulted in a 83.8% reduction in intimal thickness (P<0.05), and a 91% reduction in intimal:medial area ratio (P<0.01). The latter treatment was also associated with a significantly higher intimal cell density (14.2±1.6×10³ nuclei/mm²) compared to animals receiving non-immune IgG (7.8±0.8×10³ nuclei/mm²; P<0.025), although intimal and medial cell proliferation indices were not significantly different between the groups (P>0.05). Our results suggest that in this particular model, PDGF-BB and bFGF are the major factors controlling neointimal hyperplasia, and that these growth factors are operating principally via an effect on smooth muscle cell migration and extracellular matrix protein accumulation.     

球囊成形术后氯沙坦对兔血管内膜增殖及巨噬细胞表达的影响

目的　通过观察AT1受体的特异性拮抗剂氯沙坦 (Losartan)对兔腹主动脉球囊成形术后内膜增殖和巨噬细胞表达的影响 ,探讨氯沙坦治疗血管再狭窄的机制。方法　采用内皮剥脱加高脂饮食 (含 1 5 %胆固醇 )喂养 8周制作兔腹主动脉粥样硬化膜型 ,然后对狭窄部位行球囊成形术。术后氯沙坦组给予氯沙坦 10mg·kg-1·day-1口服 ,对照组喂生理盐水。 4周后取腹主动脉行组织形态学观察 ,用免疫组织化学方法分析巨噬细胞。结果　对照组内膜厚度 /中膜厚度比值为 0 65± 0 17,氯沙坦组则减少为0 44± 0 11(P <0 0 1) ,对照组内膜面积 /中膜面积比值为 0 74± 0 16,氯沙坦组则减少为 0 5 4± 0 13(P <0 0 1)。氯沙坦组新生内膜中巨噬细胞数亦较对照组显著减少 (P <0 0 1)。结论　氯沙坦通过抑制AngⅡ的作用进而抑制巨噬细胞的浸润 ,抑制炎症反应 ,从而减轻再狭窄     

Can supplementation of diet with omega-3 polyunsaturated fatty acids reduce coronary angioplasty restenosis rate?

The objective of this blinded, randomized, prospective study was to assess whether supplementation of normal diet with omega-3 polyunsaturated fatty acids can reduce angiographically defined restenosis following coronary angioplasty. The study included all patients undergoing coronary angioplasty in this institution between January 1988 and January 1989. One hundred and twenty patients enrolled, 60 in each treatment group. All were randomized to either supplementation of normal diet with 3 g of omega-3 polyunsaturated fatty acids per day started 1-2 days prior to angioplasty and continued for 6 months (treatment group), or to receive standard therapy only (control group). Quantitative angiographically defined restenosis was assessed at 6 months post angioplasty. Restenosis occurred in 27.8% (95% CI 18.0-37.7%) of lesions in the treatment group and in 28.3% (CI 16.9-39.7%) of lesions in the control group, but the difference was not statistically significant. The study showed that diet supplemented with 3 g of omega-3 polyunsaturated fatty acids started 1-2 days preceding angioplasty does not reduce angiographically defined restenosis rate.     

卡托普利对血管成形术后再狭窄作用的实验研究

目的探讨卡托普利对血管成形术后再狭窄的干预作用。方法SD雄性大鼠60只,分单损组、干预组和对照组。单损组采用改良导丝法制作大鼠颈动脉再狭窄模型。干预组将卡托普利研磨成粉状,生理盐水稀释配制成5mg/ml溶液,分别于制模前6 d开始按10 mg/(kg.d)剂量经灌胃针给予大鼠至术后各时间点。对侧颈总动脉作为假手术对照组。每组各时间点6只大鼠,于制模后1天、4天、7天、14天及28天原位灌注固定取材。根据HE染色标本情况,选血管形态结构完整的50个标本,进行HE染色,采用病理图像分析系统染色片进行形态计量分析。结果损伤后从第7天起新生内膜厚度和面积逐渐增加,到28天达峰值;与单损组比较,干预组血管壁三层厚度无显著差别,干预组第14、28天新生内膜面积显著减低。狭窄率于血管损伤后逐渐增加,到28天达峰值,与单损组比较,干预组在14天和28天狭窄率明显变小,各时间点内弹力板面积、外弹力板面积及重塑指数两组之间无显著差别。结论卡托普利减小大鼠颈动脉损伤后新生内膜面积及狭窄率,抑制新生内膜形成,但不改变内、外弹力板面积及重塑指数,不影响血管收缩性重塑。     

Fluid and solid mechanical implications of vascular stenting

Vascular stents have emerged as an effective treatment for occlusive vascular disease. Despite their success and widespread use, outcomes for patients receiving stents are still hampered by thrombosis and restensosis. As arteries attempt to adapt to the mechanical changes created by stents, they may in fact create a new flow-limiting situation similar to that which they were intended to correct. In vitro fluid mechanics and solid mechanics studies of stented vessels have revealed important information about how stents alter the mechanical environment in the arteries into which they are placed. Adverse nonlaminar flow patterns have been demonstrated as well as remarkably high stress concentrations in the vessel wall. In vivo studies of stented vessels have also shown a strong relationship between stent design and their dynamic performance within arteries. Alterations in pressure and flow pulses distal to the stent have been observed, as well as regional changes in vascular compliance. Considering the influence of flow and stress on the vascular response and the suboptimal clinical outcomes associated with stenting, knowledge gained from stent/artery mechanics studies should play an increasingly important role in improving the long-term patency of these devices. © 2002 Biomedical Engineering Society. PAC2002: 8719Rr, 8780-y, 8719Uv     

冠脉内支架临床发展策略

冠脉内支架是临床上预防ＰＴＣＡ并发症的有效措施，但金属支架固有的血栓菜成原性和对血管壁组织的永久性刺激可导致院内心脏事件和再狭窄。为解决上述问题，作者提出，血管内支架联合靶向药物传输离子照射或基因治疗、基因修饰的内皮细胞的种植支架、吱物可吸收缓释药物支架材料研制为临床冠脉内支架开辟了广阔的发展前景。